Skip to main content
. 2024 Nov 12;7(2):101268. doi: 10.1016/j.jhepr.2024.101268

Fig. 2.

Fig. 2

Cumulative incidence of HCC (before PMS) (Kaplan-Meier analysis).

(A) All patients taking ETV, TDF, or TAF. (B) Patients with liver cirrhosis. (C) Patients without liver cirrhosis. ETV, entecavir; HCC, hepatocellular carcinoma; PMS, propensity score matching; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.